Disclosures

**Dr. Harold E. Bays:** Dr. Bays’ research site received research grants from Amarin, Amgen, Ardea, Arisaph, California Raisin Marketing Board, Catabasis, Cymabay, Eisai, Elcelyx, Eli Lilly, Esperion, Gilead, Hanmi, Hisun, Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Merck, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Sanofi, Takeda, TIMI, VIVUS, and Wpu Pharmaceuticals. Dr. Bays served as a consultant and/or speaker to Amarin, Amgen, AstraZeneca, Bristol Meyers Squibb, Catabasis, Daiichi Sankyo, Eisai, Eli Lilly, Isis, Merck, Novartis, NovoNordisk, Omthera, Regeneron, Sanofi, VIVUS, and WPU.

**Dr. Peter H. Jones:** Dr. Jones received honoraria as a consultant and/or speaker from AstraZeneca, Daiichi Sankyo Inc., Merck and Co., and Sanofi/Regeneron. Dr. Jones served on the advisory board for Atherotech Diagnostic Lab.

**Dr. W. Virgil Brown:** Dr. Brown received consulting fees from Amgen, Genzyme, Pfizer Inc., LipoScience Inc., Merck and Co., Catabasis, Glaxo SmithKline, and Medintelligence. Dr. Brown received speaker honoraria from LipoScience Inc., Merck and Co., and Vindico.

**Dr. Terry A. Jacobson:** Dr. Jacobson received consulting fees from Merck and Co., Amarin, AstraZeneca, and Regeneron/Sanofi-Aventis.

**Dr. Caroline M. Apovian:** N/A at this time.

**Dr. Karen E. Aspry:** Dr. Aspry has no disclosures to report.

**Dr. Christie M. Ballantyne:** Dr. Ballantyne received research grants from Abbott Laboratories, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, diaDexus Inc., Genentech, GlaxoSmithKline, Kowa Pharmaceuticals, Merck & Co., National Institute of Health, Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pfizer, Regeneron, Roche, Sanofi-Synthelabo, and Takeda Pharmaceuticals. He received consulting fees from Abbott Laboratories, Aegerion, Amarin, Amgen, Astra-Zeneca, Esperion, Genzyme, Kowa Pharmaceuticals America, Merck and Co., Novartis Pharmaceuticals, Omthera, Pfizer, Regeneron, Resverlogix, Roche, Sanofi-Synthelabo, and Genentech. Dr. Ballantyne received speaker honoraria from Abbott Laboratories, Aegerion, Amarin, AstraZeneca, Cerenis, Esperion, Genentech, Genzyme, Merck and Co., Pfizer, Regeneron, and Sanofi-Synthelabo.

**Dr. Keith C. Ferdinand:** Dr. Ferdinand has no disclosures to report.

**Dr. JoAnne M. Foody:** Dr. Foody received consulting fees from Merck and Co. and Pfizer Inc.

**Dr. Anne C. Goldberg:** Dr. Goldberg received research grants as a principal investigator from Amarin, Abbott Laboratories, GlaxoSmithKline, Genzyme/ISIS, Amgen, Genentech, Regeneron/Sanofi-Aventis, and Merck and Co. Dr. Goldberg received honoraria as an author from Merck and Co. Dr. Goldberg received consultant honoraria from AstraZeneca, UniQure, and Tekmira.

**Dr. Ronald B. Goldberg:** Dr. Goldberg was a speaker for Panavision.

**Dr. Antonio M. Gotto:** Dr. Gotto received consulting fees from DuPont, Aegerion, Arisaph, Janssen Pharmaceuticals Inc., Kowa Pharmaceuticals America, Merck and Co., Pfizer, Roche, and Vatera Capital. Dr. Gotto served on the Board of Directors for Esperion.
Dr. John R. Guyton: Dr. Guyton has ownership interest with Abbott.

Dr. Matthew K. Ito: Dr. Ito received a research grant as a principal investigator with Kowa Pharmaceuticals. He received consulting honorarium for Pfizer.

Dr. Penny Kris-Etherton: Dr. Kris-Etherton was on the advisory board for the California Walnut Commission and received advisory board honoraria from McDonald’s Global Advisory Council.

Mr. Ralph LaForge: Mr. LaForge received speaker honorarium from AstraZeneca.

Dr. James M. McKenney: Dr. McKenney received research grants from Sanofi-Aventis, Regeneron, Amgen, Pfizer, and Lilly.

Dr. Patrick M. Moriarty: Dr. Moriarty received consulting fees or honoraria from Abbott Laboratories and Merck Co. He received grand research support from Abbott Laboratories, AstraZeneca, B. Braun Medical Inc., Genzyme, Kaneka Pharma America LLC, Regeneron, and Sanofi-Aventis. Dr. Moriarty received consulting salary from B. Braun Medical Inc.

Dr. Pamela B. Morris: Dr. Morris has received speaker and/or advisory board honoraria from AstraZeneca, LipoScience, Aegerion, and Genzyme.

Dr. Carl E. Orringer: Dr. Orringer received consulting fees from Merck and Co.

Dr. Robert S. Rosenson: Dr. Rosenson received consulting fees as part of the advisory board for AstraZeneca, Amgen, Sanofi, Sticares ACT, LipoScience, Kowa Pharmaceuticals, Eli Lilly, Regeneron, and Janssen. Dr. Rosenson received research grants from AstraZeneca, Roche, and Amgen. He received royalty as an author with UpToDate Inc. and had ownership interest with LipoScience Inc.

Ms. Joyce L. Ross: Ms. Ross received speaker and/or consultant honoraria from Abbott Laboratories, Genzyme, and Kowa Pharmaceuticals. Ms. Ross was a part of the speakers bureau for AstraZeneca, Practice Point, and Amarin.

Dr. Joseph J. Saseen: Dr. Saseen received advisory board honorarium from AstraZeneca.

Dr. Paul D. Thompson: Dr. Thompson has received consulting fees and/or honoraria from

Dr. James A. Underberg: Dr. Underberg received honoraria for serving on the advisory board and/or speakers bureau for GlaxoSmithKline, Daiichi Sankyo Inc., Kowa Pharmaceuticals, LipoScience Inc., Merck and Co., and Novartis. Dr. Underberg received consulting honoraria and/or consulting fees from LipoScience Inc., Genzyme, News Corporation, Publicis Inc., Guidepoint Global, Eli Lilly and Co., Amarin, Aegerion, Novartis, and AstraZeneca. Dr. Underberg received research honorarium from Genzyme.

Dr. Robert A. Wild: Dr. Wild received consulting honoraria from National Institutes of Health, Food and Drug Administration, and Atherotech Inc.

Dr. Kaye-Eileen Willard: Dr. Willard received financial support from Merck.

Dr. Don P. Wilson: Dr. Wilson received speaker honorarium from Osler Institute and received consulting fees for being on the advisory board of Aegerion Pharmaceuticals. Dr. Wilson received research grants from Merck Sharp & Dohme and Novo Nordisk Inc.